Executive Summary

In September 2003 and February 2004, EntreMed announced the signing of two separate licensing deals for Endostatin (and Angiostatin). The first of the two deals went to Oxford BioMedica and the second to Alchemgen Therapeutics. What is the actual value of these phase II candidates? BioSeeker Group assesses Endostatin and gives you an independent and unbiased valuation. 

Endostatin was one of the first naturally derived antiangiogenic proteins, discovered under EntreMed funding and demonstrated to cause tumor shrinkage by cutting off the blood supply. Initially the drug was expected to be launched in 2007. In 1998 Endostatin was at its heights, and declared through several sources, as a biological drug with the potential of being a cure of cancer. Despite early enthusiasm for Endostatin, as safe and effective anticancer drugs, results from clinical trials have been partially disappointing. Clinical phase II trials have commenced that will define whether the Endostatin strategy will hold. 

BioSeeker Group believes that an independent, unbiased valuation of an interesting therapeutic candidate is of immense value in the process of choosing different licensing, benchmarking or collaboration projects. All of BioSeeker Group's valuations are based on 6 fundamental aspects of the process by which an invention is developed into a therapeutic reality. 

> Scientific Background

> IP Situation

> R&D Progress

> Competitive Landscape

> Collaboration Strength

> Company Structure  

Description of all the 6 above mentioned aspects are included in the report and in this manner the report provides a general description, structure and analysis of the field as well as a specific valuation.  

In this specific valuation report, we have chosen study a biological drug that was one of the first endogenous molecules reported to have an anti-angiogenetic property to more closely. Although the molecular mechanism of Endostatin is not yet clear many endogenous inhibitors of angiogenesis, including Endostatin, seem to work partly through the alpha-v beta-3 receptor further emphasizing the critical role of this receptor in angiogenesis. Integrin antagonists have as well been studied in detail. We review these candidate's possibilities and opportunities as well as competition and drawbacks for targeting the integrin. In addition, activities and progress utilizing biological strategies to inhibit vascular endothelial cell growth for the treatment of cancer are described. 

For your convenience, data is summarized in tables and graphs to enhance the overall view of this field.  

BioSeeker Group has identified a total of 114 different therapies that have been developed utilizing antiangiogenetic or vascular targeting strategies. The progress of 25 different therapeutic candidates related specifically to the integrin inhibitory drug pipeline are described in detail. 

BioSeeker Group produced this valuation without interference from the company (EntreMed). BioSeeker Group has on some occasions made specific requests to experts in the field to clarify particular questions raised during the analysis. BioSeeker Group has not designed this analysis upon a specific customer request. 

Activities from approximately 50 companies are included in the report. 

The most prominent companies included in the report are: Adherex Technologies, Attenuon, Bayer AG, Centocor, Claragen, Curagen, Eisai Co, ILEX Oncology, Medimmune, Merck, Pharmacia, Protein Design Labs, Sigma Tau, Telik. 

Pages: 56

Published: Feb 2004 

Publisher: BioSeeker 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/BioSeeker.html#a103